Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Oral TP-271 in Healthy Adults
NCT03024034Phase 1Completed
- Sponsor
- Tetraphase Therapeutics
- Start
- Mar 2017
- Primary completion
- Dec 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TP-271 in bacterial infection and community-acquired bacterial pneumonia (CAP) (7 arms), sponsored by Tetraphase Therapeutics. Primary endpoints: Adverse Events, Physical Examinations and 3 more. Started Mar 2017; status: completed.
02
Drugs
TP-271
03
Conditions
bacterial infectioncommunity-acquired bacterial pneumonia (CAP)
Beyond the preview
Go deeper on NCT03024034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03024034.